A novel family of negative and positive allosteric modulators of NMDA receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 335, Issue 3, 2010, Pages 614-621

  Costa, Blaise Mathias ^a   Irvine, Mark W ^b   Fang, Guangyu ^b   Eaves, Richard J ^b   Mayo Martin, Marie Belen ^b   Skifter, Donald A ^a,c   Jane, David E ^b   Monaghan, Daniel T ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c Complete Genomics Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BROMO 2 HYDROXY 6 PHENYLNAPHTHALENE 3 CARBOXYLIC ACID; 3,5 DIHYDROXYNAPHTHALENE 2 CARBOXYLIC ACID; 6 BROMO 2 OXO 2H CHROMENE 3 CARBOXYLIC ACID; 9 (4 METHYLPENT 1 YL)PHENANTHRENE 3 CARBOXYLIC ACID; 9 CYCLOPROPYLPHENANTHRENE 3 CARBOXYLIC ACID; 9 IODOPHENANTHRENE 3 CARBOXYLIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2C; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2D; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NAPHTHALENE DERIVATIVE; NSC 339614; PHENANTHRENE DERIVATIVE; UBP 512; UBP 551; UBP 608; UBP 618; UBP 646; UBP 710; UNCLASSIFIED DRUG;

ARTICLE; DRUG ANTAGONISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FEMALE; IN VITRO STUDY; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ALLOSTERIC REGULATION; ANIMALS; BINDING SITES; BINDING, COMPETITIVE; EXCITATORY POSTSYNAPTIC POTENTIALS; GLUTAMIC ACID; GLYCINE; HUMANS; MEMBRANE TRANSPORT MODULATORS; OOCYTES; PATCH-CLAMP TECHNIQUES; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, N-METHYL-D-ASPARTATE; RECOMBINANT FUSION PROTEINS; RNA, COMPLEMENTARY; SEQUENCE DELETION; XENOPUS LAEVIS;

EID: 78649582336     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.174144     Document Type: Article

References (41)

1. Ahmed AH and Oswald RE (2010) Piracetam defines a new binding site for allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors. J Med Chem 53:2197-2203.
2. Balannik V, Menniti FS, Paternain AV, Lerma J, and Stern-Bach Y (2005) Molecular mechanism of AMPA receptor noncompetitive antagonism. Neuron 48:279-288.
3. Baron A, Montagne A, Cassé F, Launay S, Maubert E, Ali C, and Vivien D (2010) NR2D-containing NMDA receptors mediate tissue plasminogen activator-promoted neuronal excitotoxicity. Cell Death Differ 17:860-871.
4. Brickley SG, Misra C, Mok MH, Mishina M, and Cull-Candy SG (2003) NR2B and NR2D subunits coassemble in cerebellar Golgi cells to form a distinct NMDA receptor subtype restricted to extrasynaptic sites. J Neurosci 23:4958-4966.
5. Buller AL, Larson HC, Schneider BE, Beaton JA, Morrisett RA, and Monaghan DT (1994) The molecular basis of NMDA receptor subtypes: native receptor diversity is predicted by subunit composition. J Neurosci 14:5471-5484.
6. Chen M, Lu TJ, Chen XJ, Zhou Y, Chen Q, Feng XY, Xu L, Duan WH, and Xiong ZQ (2008) Differential roles of NMDA receptor subtypes in ischemic neuronal cell death and ischemic tolerance. Stroke 39:3042-3048.
7. Cull-Candy S, Brickley S, and Farrant M (2001) NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol 11:327-335.
8. Davis M, Ressler K, Rothbaum BO, and Richardson R (2006) Effects of D-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry 60:369-375.
9. DeRidder MN, Simon MJ, Siman R, Auberson YP, Raghupathi R, and Meaney DF (2006) Traumatic mechanical injury to the hippocampus in vitro causes regional caspase-3 and calpain activation that is influenced by NMDA receptor subunit composition. Neurobiol Dis 22:165-176.
10. Dingledine R, Borges K, Bowie D, and Traynelis SF (1999) The glutamate receptor ion channels. Pharmacol Rev 51:7-61.
11. Gielen M, Siegler Retchless B, Mony L, Johnson JW, and Paoletti P (2009) Mechanism of differential control of NMDA receptor activity by NR2 subunits. Nature 459:703-707.
12. Hardingham GE and Bading H (2003) The Yin and Yang of NMDA receptor signalling. Trends Neurosci 26:81-89.
13. Hizue M, Pang CH, and Yokoyama M (2005) Involvement of N-methyl-D-aspartatetype glutamate receptor epsilon1 and epsilon4 subunits in tonic inflammatory pain and neuropathic pain. Neuroreport 16:1667-1670.
14. Hrabetova S, Serrano P, Blace N, Tse HW, Skifter DA, Jane DE, Monaghan DT, and Sacktor TC (2000) Distinct NMDA receptor subpopulations contribute to long-term potentiation and long-term depression induction. J Neurosci (Online) 20:RC81.
15. Jane DE, Tse HW, Skifter DA, Christie JM, and Monaghan DT (2000) Glutamate receptor ion channels: activators and inhibitors. Handb Exp Pharmacol 147:415-478.
16. Kalia LV, Kalia SK, and Salter MW (2008) NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol 7:742-755.
17. Khosravani H, Zhang Y, Tsutsui S, Hameed S, Altier C, Hamid J, Chen L, Villemaire M, Ali Z, Jirik FR, et al. (2008) Prion protein attenuates excitotoxicity by inhibiting NMDA receptors. J Gen Physiol 131:i5.
18. Koutsilieri E and Riederer P (2007) Excitotoxicity and new antiglutamatergic strategies in Parkinson's disease and Alzheimer's disease. Parkinsonism Relat Disord 13 (Suppl 3):S329-S331.
19. Laube B, Kuhse J, and Betz H (1998) Evidence for a tetrameric structure of recombinant NMDA receptors. J Neurosci 18:2954-2961.
20. Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, and Strittmatter SM (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457:1128-1132.
21. Lindsley CW, Shipe WD, Wolkenberg SE, Theberge CR, Williams DL, Jr., Sur C, and Kinney GG (2006) Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Curr Top Med Chem 6:771-785.
22. Lozovaya NA, Grebenyuk SE, Tsintsadze TSh, Feng B, Monaghan DT, and Krishtal OA (2004) Extrasynaptic NR2B and NR2D subunits of NMDA receptors shape 'superslow' afterburst EPSC in rat hippocampus. J Physiol 558:451-463.
23. 2+ and NR1 antagonist. Proc Natl Acad Sci USA 105:12563-12568.
24. Momiyama A (2000) Distinct synaptic and extrasynaptic NMDA receptors identified in dorsal horn neurones of the adult rat spinal cord. J Physiol 523:621-628.
25. Monaghan DT, Bridges RJ, and Cotman CW (1989) The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol 29:365-402.
26. Monaghan DT, Zhao H, Gautam V, Sun H, and Mayhan W (2010) Deletion of the NMDA receptor subunit GluN2D leads to reduced cell death in the cerebral cortex in the mouse middle cerebral artery occlusion model. Soc Neurosci Abstr 36:873.2.
27. Monyer H, Burnashev N, Laurie DJ, Sakmann B, and Seeburg PH (1994) Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12:529-540.
28. Monyer H, Sprengel R, Schoepfer R, Herb A, Higuchi M, Lomeli H, Burnashev N, Sakmann B, and Seeburg PH (1992) Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science 256:1217-1221.
29. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, and Howells DW (2006) 1,026 experimental treatments in acute stroke. Ann Neurol 59:467-477.
30. Paoletti P, Perin-Dureau F, Fayyazuddin A, Le Goff A, Callebaut I, and Neyton J (2000) Molecular organization of a zinc binding N-terminal modulatory domain in a NMDA receptor subunit. Neuron 28:911-925.
31. Papadia S, Soriano FX, Léveillé F, Martel MA, Dakin KA, Hansen HH, Kaindl A, Sifringer M, Fowler J, Stefovska V, et al. (2008) Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat Neurosci 11:476-487.
32. Rachline J, Perin-Dureau F, Le Goff A, Neyton J, and Paoletti P (2005) The micromolar zinc-binding domain on the NMDA receptor subunit NR2B. J Neurosci 25:308-317.
33. Salter MG and Fern R (2005) NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury. Nature 438:1167-1171.
34. Sanacora G, Zarate CA, Krystal JH, and Manji HK (2008) Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 7:426-437.
35. Terasaki Y, Sasaki T, Yagita Y, Okazaki S, Sugiyama Y, Oyama N, Omura- Matsuoka E, Sakoda S, and Kitagawa K (2010) Activation of NR2A receptors induces ischemic tolerance through CREB signaling. J Cereb Blood Flow Metab 30:1441-1449.
36. Thomas CG, Miller AJ, and Westbrook GL (2006) Synaptic and extrasynaptic NMDA receptor NR2 subunits in cultured hippocampal neurons. J Neurophysiol 95:1727-1734.
37. Tovar KR and Westbrook GL (1999) The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses in vitro. J Neurosci 19:4180-4188.
38. Villmann C and Becker CM (2007) On the hypes and falls in neuroprotection: targeting the NMDA receptor. Neuroscientist 13:594-615.
39. von Engelhardt J, Coserea I, Pawlak V, Fuchs EC, Köhr G, Seeburg PH, and Monyer H (2007) Excitotoxicity in vitro by NR2A- and NR2B-containing NMDA receptors. Neuropharmacology 53:10-17.
40. Watkins JC, Davies J, Evans RH, Francis AA, and Jones AW (1981) Pharmacology of receptors for excitatory amino acids. Adv Biochem Psychopharmacol 27:263-273.
41. Yuan H, Hansen KB, Vance KM, Ogden KK, and Traynelis SF (2009) Control of NMDA receptor function by the NR2 subunit amino-terminal domain. J Neurosci 29:12045-12058.